申请人:Board of Regents, The University of Texas System
公开号:US06355823B1
公开(公告)日:2002-03-12
The compounds of formula (I) are hydrophilic aryl phosphate, thiophosphate, and aminophosphate intestinal apical membrane Na-mediated phosphate co-transportation inhibitors. The compounds can be administered orally, where they act to inhibit Na-dependent phosphate uptake in the intestines, or internally, where they interact with the phosphate control functions of the kidneys and parathyroid. They are therefore useful for inhibiting sodium-mediated phosphate uptake, reducing serum PTH, calcium, calcitriol, and phosphate, and treating renal disease in an animal, including a human.
式(I)的化合物是亲水性芳基磷酸酯、硫代磷酸酯和氨基磷酸酯肠道顶端膜Na介导的磷共转运抑制剂。这些化合物可以经口给药,在那里它们作用于抑制肠道中的Na依赖性磷酸摄取,或者内部给药,在那里它们与肾脏和甲状旁腺的磷酸盐控制功能相互作用。因此,它们对于抑制钠介导的磷酸盐摄取、降低血清PTH、钙、活性维生素D和磷酸盐,并在动物(包括人类)中治疗肾脏疾病是有用的。